文献速递核素与放射性配体治疗肿瘤 PET/CT

225Ac-曲妥珠单抗预照射球体可改善225Ac脂质体穿透性及MIRDcell对药物鸡尾酒反应的预测

Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails.
PubMed 文献 · J Nucl Med · 2025-08-01

本研究利用MIRDcell版本4模拟多细胞球体经225Ac放射性药物鸡尾酒治疗后的存活分数,并比较225Ac-曲妥珠单抗与225Ac脂质体不同活性分布的效果。结果显示,先用6.5 kBq/mL 225Ac-曲妥珠单抗预处理可使球体中心0至100微米范围内225Ac脂质体衰变总数增加42%,且基于预照射后脂质体穿透数据的MIRDcell预测与实验数据更匹配。人工智能优化发现,单用225Ac脂质体虽可灭活球体内全部癌细胞,但所需总衰变数比225Ac-曲妥珠单抗与225Ac脂质体鸡尾酒多44%。

要点

  • 先用6.5 kBq/mL 225Ac-曲妥珠单抗预处理,球体中心0至100微米内225Ac脂质体衰变总数增加42%。
  • 基于预照射后脂质体穿透数据的MIRDcell预测与实验球体生长数据更匹配。
  • 单用225Ac脂质体灭活全部癌细胞所需总衰变数比鸡尾酒多44%。

核心结论

  • 225Ac-曲妥珠单抗预处理可增强225Ac脂质体的穿透性,优化穿透至微转移灶的策略对载体鸡尾酒放射性药物治疗重要。
  • 与单药相比,可能需要放射性药物鸡尾酒来消除循环肿瘤细胞、播散性肿瘤细胞和微转移灶。

研究设计与样本

  • 使用MIRDcell版本4模拟多细胞球体经225Ac放射性药物鸡尾酒治疗后的细胞存活分数。
  • 球体经不同活性浓度的[225Ac]Ac-DOTA-SCN-曲妥珠单抗和225Ac-DOTA包裹脂质体处理,总活性浓度保持13.75 kBq/mL不变,评估脂质体与抗体间5种活性分布:各载体上总活性的0%、30%、50%、70%和100%。
  • 利用荧光替代物获取225Ac-曲妥珠单抗和225Ac脂质体进入球体的穿透数据,并重新测量以确定225Ac-曲妥珠单抗预照射是否影响脂质体的时空分布。
  • 将MIRDcell预测的存活分数与实验球体生长数据进行比较,并使用MIRDcell中的人工智能工具优化225Ac-抗体与225Ac脂质体的最佳鸡尾酒配方,以达到存活分数小于0.0001并最小化所需总衰变数。

主要发现

  • 半径为200微米的球体,先用6.5 kBq/mL 225Ac-曲妥珠单抗预处理后,距球体中心0至100微米范围内225Ac脂质体所致衰变总数增加42%。
  • 基于225Ac-曲妥珠单抗预照射后获得的脂质体穿透数据,MIRDcell预测与实验数据更匹配。
  • 人工智能优化发现,单用225Ac脂质体虽能灭活球体中所有癌细胞,但所需总衰变数比使用225Ac-曲妥珠单抗与225Ac脂质体鸡尾酒多44%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This investigation examined the factors involved in predicting the responses of micrometastases to targeted 225Ac-based therapies and in optimizing these therapies through the use of cocktails of radiopharmaceuticals (RPTs). Methods: MIRDcell version 4 was used to model the surviving fraction (SF) of cells in multicellular spheroids that were treated with cocktails of 225Ac RPTs as previously reported by Howe et al. in this journal. Spheroids were treated with varying activity concentrations of [225Ac]Ac-DOTA-SCN-trastuzumab (225Ac-trastuzumab) and 225Ac-DOTA-encapsulating liposomes (225Ac-liposomes). With the total activity concentration kept constant at 13.75 kBq/mL, 5 different activity distributions among the liposomes and antibodies were evaluated: 0%, 30%, 50%, 70%, and 100% of the total activity on each carrier. Penetration of the 225Ac-trastuzumab and 225Ac-liposomes into the spheroids was obtained with fluorescent surrogates in the previous work and remeasured here to determine whether preirradiating the spheroids with 225Ac-trastuzumab affected the spatiotemporal distribution of the liposomes. These data were used to compare MIRDcell-predicted SFs with experimental spheroid outgrowths. In addition, the artificial intelligence tool in MIRDcell was used to optimize the best cocktail formulation of 225Ac-antibodies and 225Ac-liposomes to achieve SFs of less than 0.0001 while minimizing the number of total decays necessary. Results: The penetration profiles of spheroids with 200-µm radii show a 42% increase in the total number of decays attributed to 225Ac-liposomes between 0 and 100 µm from the centers of spheroids when first pretreated with 6.5 kBq/mL 225Ac-trastuzumab. The MIRDcell predictions based on liposome penetration data obtained after preirradiation with 225Ac-trastuzumab also provided a better match to the experimental data. Artificial intelligence optimization found that although 225Ac-liposomes alone are able to sterilize all the cancer cells in the spheroid, 44% more total decays are required than when using a cocktail of 225Ac-trastuzumab and 225Ac-liposomes. Conclusion: Penetration of 225Ac-liposomes was enhanced by pretreatment with 225Ac-trastuzumab, and strategies to optimize penetration into micrometastases are important for RPT therapy with carrier cocktails. RPT cocktails, as opposed to single agents, may be required to eliminate circulating tumor cells, disseminated tumor cells, and micrometastases.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tallam H, Nair R, Sarkar A, et al. Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails. J Nucl Med. 2025. PMID: 40506236. doi:10.2967/jnumed.124.269273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。